More evidence on risks of antipsychotics in adults
Commentaries provide advice about putting the results in perspective.
Two studies provide evidence that second-generation antipsychotics increase risk of death, especially when the drugs are prescribed at high doses. Another report, on the third phase of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study, found unexpected increases in blood sugar levels among patients taking aripiprazole (Abilify).
It seems lately that the news about antipsychotics is unrelentingly disappointing. However, editorials accompanying two of the studies help put results in perspective and offer practical advice for clinicians.